IRF1 expression
|
Melanoma
|
IRF1 expression
|
Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
IRF1 expression
|
Melanoma
|
IRF1 expression
|
Melanoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
IRF1 expression
|
Melanoma
|
IRF1 expression
|
Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|